
    
      This is a single-arm, open-label, phase 3 study to assess the contraceptive efficacy of
      relugolix combination therapy (relugolix 40 milligrams [mg], estradiol [E2] 1 mg, and
      norethindrone acetate [NETA] 0.5 mg).
    
  